Motilal Oswal retains Buy on Cyient DLM: Here’s why…

The brokerage firm, Motilal Oswal has retained its “Buy” rating on Cyient DLM’s stock, setting a target price of Rs 700. According to them, the company’s consistent growth in key verticals and has potential to attract large global clients in the near future.

Motilal Oswal on Cyient DLM

Motilal Oswal has revised its earnings estimates for Cyient DLM, reducing projections for FY25, FY26, and FY27 by 14%, 25%, and 26%, respectively. The revision comes after the ongoing challenges in order flows, lower margins, and uncertainties around securing large orders in the near term.

“The softness in order flows, lower margins due to unfavorable operating leverage, and uncertainty around large order inflows in the near term have prompted us to revise our estimates,” the brokerage in its report said.

However, the brokerage remains confident about the company’s long-term potential. “We retain our BUY rating on the stock with a target price of Rs 700, valuing it at 31x FY27E EPS,” added the brokerage firm in its report.

Looking ahead, the integration of Altek is expected to provide a significant boost. For Q4FY25, Motilal Oswal estimates 38% growth in consolidated revenue and a 47% rise in EBITDA, highlighting the potential impact of recent acquisitions.

Also ReadIREDA board approves raising Rs 5000 crore via QIP Cyient DLM Q3 performance

Cyient DLM announced its Q3 results on January 21. In the Q3FY25, the company reported a 38.38% YoY growth in revenue, which stood at Rs 444.24 crore.

However, profit declined 40.4% YoY to Rs 10.99 crore, reflecting margin pressures. On a QoQ basis, revenue saw a 14.07% increase, but profit dropped 28.87%.

Cyient DLM Vs Nifty 50

The share price of Cyient DLM has struggled compared to the benchmark indices Nifty 50. Cyient DLM share price today closed at Rs 511.10.

Over the last 5 days, the share price of the company dropped by 14.96% and in the past six months, the stock declined by 31.95%. On a yearly basis, it is down by 21.14%.

In comparison, the Nifty 50, the index 0.10% in the last five days and 5.23% over six months, while posting an annual gain of 9.23%.

 » Read More

Related Articles

Mphasis posts modest revenue, profit growth in Q3

Mphasis reported a sequential revenue growth of 0.8% to Rs 3,561.3 crore and a net profit of Rs 427.9 crore, up 1.1%, for the quarter ended December.  “We continue to stay focused on driving deal activity and closures, as we get on the other side of the macro cycle. AI is driving a fundamental shift

Q3FY25 Results: Thyrocare reports 30 percent rise in profit; Revenue stood at Rs 165.9 Crore

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY. According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology

Gold prices soar to new peak of Rs 82,900 per 10 gm; silver drops by Rs 500

Gold prices rose Rs 170 to hit a fresh record high of Rs 82,900 per 10 grams in the national capital on Thursday amid a positive global trend, according to the All India Sarafa Association. The precious metal had closed at Rs 82,730 per 10 grams on Wednesday. In about one year, the precious metal

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Mphasis posts modest revenue, profit growth in Q3

Mphasis reported a sequential revenue growth of 0.8% to Rs 3,561.3 crore and a net profit of Rs 427.9 crore, up 1.1%, for the quarter ended December.  “We continue to stay focused on driving deal activity and closures, as we get on the other side of the macro cycle. AI is driving a fundamental shift

Q3FY25 Results: Thyrocare reports 30 percent rise in profit; Revenue stood at Rs 165.9 Crore

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY. According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology

Gold prices soar to new peak of Rs 82,900 per 10 gm; silver drops by Rs 500

Gold prices rose Rs 170 to hit a fresh record high of Rs 82,900 per 10 grams in the national capital on Thursday amid a positive global trend, according to the All India Sarafa Association. The precious metal had closed at Rs 82,730 per 10 grams on Wednesday. In about one year, the precious metal

Good news for taxpayers! Govt removes THESE difficulties to ensure more tax cases are settled – Check details!

Good news for taxpayers! The Finance Ministry has made some changes to the Direct Tax Vivad Se Vishwas Scheme, 2024, removing “difficulties” that arose due to certain situations for taxpayers. This update in the scheme will bring relief to taxpayers who wanted to apply for the scheme but could not do so earlier. “CBDT…makes the

Johnnie Walker-maker United Spirits posts Q3 profit decline of 4.29% to Rs 335 crore, revenue up 11.06% YoY

United Spirits, which makes Smirnoff vodka, on Thursday reported a profit of Rs 335 crore for the third quarter of FY25, posting a decline of 4.29 per cent in comparison to Rs 350 crore during the corresponding quarter of previous financial year. It posted revenue from operations at Rs 7,732 crore, reporting a growth of